Why This Summit Is Unmissable for Academics

Shape the Next Generation of RNA-Targeted Therapeutics.

Connect your research with the biotech and pharma organizations translating RNA biology into therapeutic programs. The next generation of RNA-targeted therapeutics will emerge from closer collaboration between academia and industry.

Join the biotech and pharma teams translating RNA biology into therapeutic programs and discover how your research can influence drug discovery, target validation, structure prediction, and translational development efforts.

Academics Discussing

Challenges We Help Solve

Challenges Solved RNA DDD Number 1

Translating RNA Biology Into Therapeutic Applications

Understand how industry is transforming fundamental discoveries into drug development opportunities.

Challenges Solved RNA DDD Number 2

Understanding Industry's Most Pressing Bottlenecks

Learn where pharma and biotech organizations need new scientific solutions.

Challenges Solved RNA DDD Number 3

Advancing RNA Structure & Interaction Analysis

Explore the latest technologies used to characterize RNA structures, binding pockets, conformational dynamics, and molecular interactions.

Challenges Solved RNA DDD Number 4

Identifying High-Impact Research Opportunities

Discover where future funding, collaboration, and industry interest are likely to emerge.

Challenges Solved RNA DDD Number 5

Building New Industry Collaborations

Connect with organizations seeking novel technologies, targets, and platform capabilities.

Priority Sessions for Academics

Translating RNA Biology Into Therapeutically Relevant Targets

Workshop A: Identifying Functional RNA Targets at Scale to Prioritize Therapeutically Relevant Discovery Hypothesis

Pre-Conference Day

Speakers:

  • Dalya Gartzman, Chief Executive Officer & Co-Founder, Renasis Bio
  • Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics
  • Stefan Schiesser, Director, Medicinal Chemistry, AstraZeneca

Understand how industry evaluates RNA targets, prioritizes biological relevance, and transforms fundamental RNA biology into therapeutic opportunities.

Dalya Gartzman Renasis Bio CEO biotech innovation leader
Dominic Reynolds Remix Therapeutics CSO RNA modulation biotech
Stefan Schiesser AstraZeneca Director Medicinal Chemistry speaking at drug discovery conference
Renasis Bio
Remix Therapeutics
AstraZeneca attending RNA drug discovery summit biotech conference
Understanding RNA Structure & Druggability

Modelling Approaches to Understand RNA Structure, Dynamics & Small Molecule Binding to Guide Target Selection & Improve Small Molecule Design

Conference Day One

Speaker:

  • Paraskevi Gkeka, Distinguished Scientist, Group Head CADD, Sanofi

Explore how computational modelling, RNA dynamics, and binding-site prediction are driving the next generation of RNA-targeted drug discovery.

Paraskevi Gkeka Sanofi Group Head CADD computational drug design expert
Sanofi
Characterizing Functionally Meaningful RNA-Protein Complexes

Roundtable Discussion: Characterizing Functionally Meaningful RNA-Protein Complexes to Enable Productive Drug Discovery

Conference Day Two

Moderator:

  • Nikolai Naryshkin, Chief Scientific Officer, Ribonaut Therapeutics

Discover how industry is connecting RNA structure, protein interactions, and functional biology to identify mechanisms most likely to generate therapeutic success.

Nikolai Naryshkin Ribonaut Therapeutics CSO RNA splicing expert
Ribonaut Therapeutics

Benchmark Your Strategy Against Peers

Questions you could ask your peers to benchmark against them:

Which RNA targets are attracting the most industry investment?

What translational evidence matters most to drug developers?

Which discovery technologies have the highest adoption?

Where are the biggest opportunities for academic-industry collaboration?

Which disease areas are creating new opportunities?

What Past Attendees Say

Sanofi logo

Engaging with fellow innovators allows us to collectively address the field's challenges, explore new frontiers, and build partnerships that will define the next generation of medicines.

xForestTherapeutics logo

The highly engaged audience and the frank exchange of technical challenges made the sessions particularly valuable. It was also inspiring to see how different groups are approaching RNA-targeted small molecules from diverse angles, which made the conversations both enjoyable and thought-provoking.

Turn RNA Innovation Into Action

From identifying functional RNA targets and optimizing lead compounds to securing strategic partnerships and evaluating new modalities, this summit is designed to help you overcome the challenges facing the next generation of RNA-targeted therapeutics.

Explore the latest scientific advances, connect with peers facing similar challenges, and leave with practical insights you can immediately apply to your research, pipeline, and business strategy.

Secure your place today or explore the full agenda to discover the sessions most relevant to you.